Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.74 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.70 |
| ▸ | GAA | P10253 | 1/20 | 0.70 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL546627 | 0.98 | HTT (0.77) | HTTKDM4EGAAHRH3ALDH1A1 | |
| SCHEMBL25062715 | 0.85 | KDM4E (0.68) | HTTKDM4EGAAHRH3ALDH1A1 | |
| SCHEMBL1243301 | 0.85 | HTT (1.00) | HTTKDM4EGAAHRH3ALDH1A1 | |
| SCHEMBL3061301 | 0.85 | KDM4E (0.68) | HTTKDM4EGAAHRH3ALDH1A1 | |
| SCHEMBL3823611 | 0.84 | HTT (0.70) | HTTKDM4EGAAHRH3ALDH1A1 | |
| SCHEMBL21044234 | 0.84 | HTT (0.70) | HTTKDM4EGAAHRH3ALDH1A1 | |
| Hydrochloric Acid SCHEMBL3500894 | 0.84 | HTT (0.97) | HTTKDM4EGAAHRH3ALDH1A1 | |
| SCHEMBL15652383 | 0.83 | KDM4E (0.70) | HTTKDM4EGAAHRH3ALDH1A1 | |
| SCHEMBL3061697 | 0.83 | KDM4E (0.66) | HTTKDM4EGAAHRH3ALDH1A1 | |
| SCHEMBL1286668 | 0.83 | KDM4E (0.66) | HTTKDM4EGAAHRH3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2395000-A1 | Benzimidazole compounds that modulate the activity of CDK, GSK and aurora kinases | Astex Therapeutics Limited (GB) | 2011-12-14 | — | — | EP | claimed |
| US-20100004232-A1 | Pharmaceutical Compounds | ASTEX THERAPEUTICS LIMITED (UK) | 2010-01-07 | — | — | US | claimed |
| EP-1727551-B1 | PHARMACEUTICAL COMPOSITION COMPRISING A BENZODIAZEPINE DERIVATIVE AND A INHIBITOR OF THE RSV FUSION PROTEIN | ARROW THERAPEUTICS LTD (GB) | 2009-09-09 | — | — | EP | claimed |
| CN-100496499-C | Pharmaceutical composition comprising a benzodiazepine derivative and an inhibitor of the RSV fusion protein | ARROW THERAPEUTICS LTD (GB) | 2009-06-10 | — | — | CN | claimed |
| EP-2049119-A2 | PHARMACEUTICAL COMBINATIONS OF 1-CYCLOPROPYL-3-[3-(5-MORPHOOLIN-4-YLMETHYL-1H-BENZOIMIDAZOL-2-YL)-1H-1-PYRAZOL-4-YL]-UREA | Astex Therapeutics Limited (GB) | 2009-04-22 | — | — | EP | claimed |
| EP-2043635-A2 | PHARMACEUTICAL COMBINATIONS | Astex Therapeutics Limited (GB) | 2009-04-08 | — | — | EP | claimed |
| CN-101379058-A | Pyrazole compounds that modulate the activity of CDK, GSK and aurora kinases | ASTEX THERAPEUTICS LTD (GB) | 2009-03-04 | — | — | CN | claimed |
| EP-1968579-A1 | PHARMACEUTICAL COMPOUNDS | Astex Therapeutics Limited (GB) | 2008-09-17 | — | — | EP | claimed |
| US-20080139536-A1 | Benzodiazepines for Treating or Preventing Rsv Infection | NOVARTIS PHARMACEUTICALS CORPORATION (US) | 2008-06-12 | — | — | US | claimed |
| US-20080132495-A1 | Pyrazole Compounds that Modulate the Activity of Cdk, Gsk and Aurora Kinases | ASTEX THERAPEUTICS LIMITED (GB) | 2008-06-05 | — | — | US | claimed |
| US-20070185096-A1 | Pharmaceutical composition comprising a benzodiazepine derivative and an inhibitor of the rsv fusion protein | NOVARTIS PHARMACEUTICALS CORPORATION (US) | 2007-08-09 | — | — | US | claimed |
| WO-2007077435-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2007-07-12 | — | — | WO | claimed |
| CN-1933841-A | Pharmaceutical composition comprising a benzodiazepine derivative and an inhibitor of the rsv fusion protein | ARROW THERAPEUTICS LTD (GB) | 2007-03-21 | — | — | CN | claimed |
| CN-1929848-A | Benzodiazepines for treating or preventing or preventing RSV infection | ARROW THERAPEUTICS LTD (GB) | 2007-03-14 | — | — | CN | claimed |
| EP-1740185-A1 | BENZODIAZEPINES FOR TREATING OR PREVENTING RSV INFECTION | Arrow Therapeutics Limited (GB) | 2007-01-10 | — | — | EP | claimed |
| EP-1727551-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A BENZODIAZEPINE DERIVATIVE AND A INHIBITOR OF THE RSV FUSION PROTEIN | Arrow Therapeutics Limited (GB) | 2006-12-06 | — | — | EP | claimed |
| WO-2006070195-A1 | PYRAZOLE COMPOUNDS THAT MODULATE THE ACTIVITY OF CDK, GSK AND AURORA KINASES | ASTEX THERAPEUTICS LIMITED (GB) | 2006-07-06 | — | — | WO | claimed |
| WO-2005089770-A1 | BENZODIAZEPINES FOR TREATING OR PREVENTING OR PREVENTING RSV INFECTION | ARROW THERAPEUTICS LIMITED (GB) | 2005-09-29 | — | — | WO | claimed |
| WO-2005090319-A1 | PROCESS FOR PREPARING BENZODIAZEPINES | ARROW THERAPEUTICS LIMITED (GB) | 2005-09-29 | — | — | WO | claimed |
| WO-2005089771-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A BENZODIAZEPINE DERIVATIVE AND A INHIBITOR OF THE RSV FUSION PROTEIN | ARROW THERAPEUTICS LIMITED (GB) | 2005-09-29 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004232-A1 | Pharmaceutical Compounds | ERBB3, ABL1, RET | HTT 3102/4885KDM4E 2063/4885GAA 3397/4885 |
| US-20070185096-A1 | Pharmaceutical composition comprising a benzodiazepine derivative and an inhibitor of the rsv fusion protein | GABRP, TSPO, GABRA1 | HTT 3035/4885KDM4E 4254/4885GAA 2238/4885 |
| US-20080132495-A1 | Pyrazole Compounds that Modulate the Activity of Cdk, Gsk and Aurora Kinases | CDK3, CDK1, AURKA | HTT 3641/4885KDM4E 1339/4885GAA 3595/4885 |
| US-20080139536-A1 | Benzodiazepines for Treating or Preventing Rsv Infection | CNR1, CBR1, CBR3 | HTT 2576/4885KDM4E 3844/4885GAA 3959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.